Superficial Femoral Artery in-Stent Restenosis Treated with Paclitaxel-Coated Balloon Angioplasty – Results of Three-Year Follow-Up

• Published in: Vascular and endovascular surgery 2023-10, Vol.57 (7), p.673-679
• Main Authors: Peclat de Oliveira, Julio Cesar, Alvim Fiorelli, Rossano Kepler, Rolim Maia Peclat, Ana Paula, Peclat de Oliveira, Lucas Maia, Oliveira, Rafael, Belczac, Sergio Quilici, Almeida, Renato Santos, Dalio, Marcelo Bellini, Joviliano, Edwaldo Edner, Gutfilen, Bianca
• Format: Article
• Language: English
• ISSN: 1538-5744; 1938-9116
• DOI: 10.1177/15385744231165877

Background In-stent restenosis remains a common and important complication after endovascular treatment of superficial femoral artery peripheral artery disease. It occurs in 14 to 35% of cases in 1 year and there is still no efficient treatment for this condition. Paclitaxel-coated balloons have shown promising results. Objective Investigate the 3 year results of superficial femoral artery in-stent restenosis treated with paclitaxel-coated balloon angioplasty, using the Lutonix™ 035 device. Methods We conducted a retrospective observational study with patients with symptomatic (Rutherford 2 to 5) superficial femoral artery in-stent restenosis, that were treated with paclitaxel-coated balloon angioplasty using the Lutonix™ 035 device, in a single center from January 2016 to December 2020. Duplex scan was used to follow the patients. Primary patency was obtained through Kaplan-Meier analysis. Mortality, and amputation rates were also evaluated. Results 105 patients were included. Two patients had technical failure and required an additional stent, and were thus excluded. 103 patients were analyzed. Primary patency was 91.26, 80.47, and 67.71%, respectively, in the first, second, and third year after the procedure. There were no deaths 30 days after the procedure. There were no major amputations during the 3 year follow-up. Conclusion Paclitaxel-coated balloon angioplasty with the Lutonix™ 035 device was a safe and effective treatment to superficial femoral artery in-stent restenoses. The results were maintained along the 3 year follow-up.